Free Trial
NASDAQ:EVGN

Evogene (EVGN) Stock Price, News & Analysis

Evogene logo
$1.49 +0.08 (+5.67%)
Closing price 07/9/2025 04:00 PM Eastern
Extended Trading
$1.45 -0.04 (-2.68%)
As of 04:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Evogene Stock (NASDAQ:EVGN)

Key Stats

Today's Range
$1.41
$1.50
50-Day Range
$1.10
$2.26
52-Week Range
$0.95
$6.80
Volume
164,519 shs
Average Volume
625,097 shs
Market Capitalization
$8.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$3.50
Consensus Rating
Buy

Company Overview

Evogene Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
40th Percentile Overall Score

EVGN MarketRank™: 

Evogene scored higher than 40% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Evogene has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Evogene has only been the subject of 1 research reports in the past 90 days.

  • Read more about Evogene's stock forecast and price target.
  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Evogene is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Evogene is -0.55, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Evogene has a P/B Ratio of 0.54. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Evogene's valuation and earnings.
  • Percentage of Shares Shorted

    7.54% of the float of Evogene has been sold short.
  • Short Interest Ratio / Days to Cover

    Evogene has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Evogene has recently increased by 320.44%, indicating that investor sentiment is decreasing significantly.
  • Dividend Yield

    Evogene does not currently pay a dividend.

  • Dividend Growth

    Evogene does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    7.54% of the float of Evogene has been sold short.
  • Short Interest Ratio / Days to Cover

    Evogene has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Evogene has recently increased by 320.44%, indicating that investor sentiment is decreasing significantly.
  • News Sentiment

    Evogene has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.56 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 2 news articles for Evogene this week, compared to 1 article on an average week.
  • Search Interest

    8 people have searched for EVGN on MarketBeat in the last 30 days. This is an increase of 700% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Evogene insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.40% of the stock of Evogene is held by insiders.

  • Percentage Held by Institutions

    Only 10.40% of the stock of Evogene is held by institutions.

  • Read more about Evogene's insider trading history.
Receive EVGN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evogene and its competitors with MarketBeat's FREE daily newsletter.

EVGN Stock News Headlines

Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve suffered financial hardship…Our President may have solved everything.
Evogene Ltd. Reports Q1 2025 Financial Results
See More Headlines

EVGN Stock Analysis - Frequently Asked Questions

Evogene's stock was trading at $1.87 at the beginning of 2025. Since then, EVGN shares have decreased by 20.3% and is now trading at $1.49.

Evogene Ltd. (NASDAQ:EVGN) posted its earnings results on Wednesday, May, 21st. The biotechnology company reported ($0.38) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.12. The biotechnology company earned $2.44 million during the quarter, compared to analysts' expectations of $4.42 million. Evogene had a negative trailing twelve-month return on equity of 102.40% and a negative net margin of 224.82%.
Read the conference call transcript
.

Shares of Evogene reverse split before market open on Thursday, July 25th 2024.The 1-10 reverse split was announced on Tuesday, July 23rd 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

Shares of EVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Evogene investors own include Tesla (TSLA), NIO (NIO), NVIDIA (NVDA), Plug Power (PLUG), Riot Platforms (RIOT) and AquaBounty Technologies (AQB).

Company Calendar

Last Earnings
5/21/2025
Today
7/09/2025
Next Earnings (Estimated)
8/20/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Chemicals
Current Symbol
NASDAQ:EVGN
CIK
1574565
Employees
140
Year Founded
N/A

Price Target and Rating

High Price Target
$3.50
Low Price Target
$3.50
Potential Upside/Downside
+134.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$16.49 million
Net Margins
-224.82%
Pretax Margin
-254.09%

Debt

Sales & Book Value

Annual Sales
$8.51 million
Price / Cash Flow
N/A
Book Value
$2.77 per share
Price / Book
0.54

Miscellaneous

Free Float
4,968,000
Market Cap
$8.00 million
Optionable
Optionable
Beta
1.58

Social Links

Elon Musk's Next Move Cover

Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.

Get This Free Report

This page (NASDAQ:EVGN) was last updated on 7/10/2025 by MarketBeat.com Staff
From Our Partners